Skip to main content

Recent News & Research

Onc Live
FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC ResearchTreatments

FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC

*January 2020* The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application (sBLA) for intravenous ramucirumab (Cyramza) injection for use in combination with erlotinib (Tarceva) in the frontline treatment of patients with metastatic non–small cell lung…
targeted oncology
Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC ResearchTreatments

Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

*December 2019* With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small cell lung cancer (NSCLC), novel options like lazertinib (YH25448), an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib has shown promise for the treatment of this patient population, according…
laurabbook@gmail.com
January 18, 2020
PR Newswire
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC ResearchTreatments

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC

*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the Ministry of Food and Drug Safety (MFDS) in Korea to initiate…
laurabbook@gmail.com
January 18, 2020
Osimertinib promising for EGFR-mutant NSCLC with leptomeningeal metastases ResearchTreatments

Osimertinib promising for EGFR-mutant NSCLC with leptomeningeal metastases

*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest. Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Republic of Korea) and study co-authors say that “osimertinib has the potential to become a…
laurabbook@gmail.com
January 18, 2020
dana farber logo
Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers FundingResearch

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer. The Chen-Huang Center is being established with a $5 million gift from Winston Chen,…
laurabbook@gmail.com
January 18, 2020
EGFR Resisters logo
Project PRIORITY: Why it matters to the EGFR-positive lung cancer community AdvocacyCoping With CancerResearch

Project PRIORITY: Why it matters to the EGFR-positive lung cancer community

*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR Resisters—a grassroots, patient-driven community dedicated exclusively to changing EGFR-positive lung cancer into a manageable chronic disease. Goal of Project PRIORITY To understand unmet needs of the EGFR-positive lung cancer…
laurabbook@gmail.com
December 20, 2019
EGFR Resisters logo
New Clinical Trials ResearchTreatments

New Clinical Trials

*November 2019* Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More information. The JNJ-372 (or JJNJ-61186372) was recently updated with the addition of Lazertinib as one of its arms to be given in combo with JNJ-372 drug or separately and is/or…
laurabbook@gmail.com
November 8, 2019